SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.00-6.4%11:37 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Casaubon who wrote (22564)1/18/2007 1:22:57 PM
From: rkrw  Read Replies (1) of 52153
 
Correct on all counts except if the drug was already approved and dirt cheap, there would have been no pricing and no reason for celg to develop. And actually celg backdoored approval in leprosy and had MM as de facto soc off label for many years.

Making a new and useful benefit out of an old drug or even a failed drug is a regular cottage industry. But pricing (and use i.p.) potential would be among the top screens when assessing opportunities. Some serious returns have been made in this area, such as kosp with niacin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News